rose bengal
Rose bengal sodium (RB) is a small molecule, halogenated xanthene being developed by Provectus Biopharmaceuticals (formerly Provectus Pharmaceuticals). It is commonly used in eye drops to stain damaged conjunctival and corneal cells and thereby identify damage to the eye. The stain is also used in the preparation of Foraminifera for microscopic analysis, allowing the distinction between forms that were alive or dead at the time of collection. A form of rose bengal is also being studied as a treatment for certain cancers and skin conditions. The cancer formulation of the drug, known as PV-10, is currently undergoing clinical trials for melanoma and breast cancer. Recently, interest in RB as a therapeutic cancer treatment has increased due to significant anti-tumor responses with direct tumor injection in human clinical trials for metastatic melanoma. In these patients, there has been the implication that RB may mount a T-cell mediated anti-tumor response and impart antigen-specific responses in distant bystander lesions. — NCATS
Clinical trial activity
14 trials · 12 clinical orgs · 0 marketing orgs
Earliest trial started Aug 1, 2005 (NCT00219843)
Timeline
Indications
Approved for
Studied for
- Acanthamoeba Keratitis · Phase 3
- Breast Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Phase 1
- Cigarette Smoking · Phase 3
- Colonic Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 1
- Dermatitis, Atopic · Phase 2
- Infections · Phase 3
- Keratitis · Phase 3
- Liver Neoplasms · Phase 1
- Lung Neoplasms · Phase 1
- Melanoma · Phase 3
- Neoplasm Metastasis · Phase 1
- Pancreatic Neoplasms · Phase 1
- Psoriasis · Phase 2
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
SMILES
O=C([O-])c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(=O)c(I)c-2oc2c(I)c([O-])c(I)cc12.[Na+].[Na+]- Mol. weight
- 1017.64 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2359093 ↗
- NCATS956575SN5L ↗
Also known as
- rose bengal disodium
- rose bengal disodium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06271772 | Phase 3 | Jul 1, 2024 | Aravind Eye Hospital, Federal University of Sao Paulo, Stanford University, University of California, San Francisco |
| NCT05110001 | Phase 3 | Jan 31, 2022 | Aravind Eye Hospital, National Eye Institute (NEI), Stanford University, University of California, San Francisco |
| NCT04837664 | Phase 3 | Jul 3, 2018 | King Saud University |
| NCT02693067 | Phase 1 | Jul 1, 2016 | Provectus Biopharmaceuticals, Inc. |
| NCT02288897 | Phase 3 | Apr 1, 2015 | Provectus Biopharmaceuticals, Inc., St. Luke's University Health Network, Bethlehem, PA |
| NCT01260779 | N/A | Dec 13, 2010 | Provectus Biopharmaceuticals, Inc. |
| NCT01247818 | Phase 2 | Dec 1, 2010 | Provectus Biopharmaceuticals, Inc. |
| NCT00986661 | Phase 1 | Oct 1, 2009 | Provectus Biopharmaceuticals, Inc., Sharp Clinical Oncology Research |
| NCT00941278 | Phase 2 | Jul 1, 2009 | Provectus Biopharmaceuticals, Inc. |
| NCT00690807 | Phase 2 | Jun 1, 2008 | Provectus Biopharmaceuticals, Inc. |
| NCT00555646 | Phase 2 | Nov 1, 2007 | Icahn School of Medicine at Mount Sinai, Provectus Biopharmaceuticals, Inc. |
| NCT00521053 | Phase 2 | Sep 1, 2007 | Melanoma Institute Australia, Provectus Biopharmaceuticals, Inc. |
| NCT00237354 | Phase 1 | Oct 1, 2005 | Provectus Biopharmaceuticals, Inc., University of Otago |
| NCT00219843 | Phase 1 | Aug 1, 2005 | Provectus Biopharmaceuticals, Inc. |
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Provectus Biopharmaceuticals, Inc. | For profit | 11 | 11 | 4 | 2005 |
| Aravind Eye Hospital | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Stanford University | Academic/Hospital | 2 | 0 | 1 | 2022 |
| University of California, San Francisco | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Federal University of Sao Paulo | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2007 |
| King Saud University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Melanoma Institute Australia | Academic/Hospital | 1 | 0 | 1 | 2007 |
| National Eye Institute (NEI) | Government | 1 | 0 | 1 | 2022 |
| Sharp Clinical Oncology Research | Academic/Hospital | 1 | 0 | 1 | 2009 |
| St. Luke's University Health Network, Bethlehem, PA | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Otago | Academic/Hospital | 1 | 0 | 1 | 2005 |